These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22617189)

  • 41. Ivabradine in heart failure--no paradigm SHIFT…yet.
    Teerlink JR
    Lancet; 2010 Sep; 376(9744):847-9. PubMed ID: 20801501
    [No Abstract]   [Full Text] [Related]  

  • 42. Does ivabradine really limit dobutamine-induced tachycardia in stable heart failure patients: parallax in significance.
    Mert KU; Mert GÖ; Başaran O; Biteker M
    Int J Cardiol; 2014 Dec; 177(2):726. PubMed ID: 25456579
    [No Abstract]   [Full Text] [Related]  

  • 43. [Electrical properties of a new beta-blocker agent, tertatolol, in man].
    Touboul P; Atallah G; Kirkorian G; Lamaud M; Moleur P
    Therapie; 1983; 38(4):371-8. PubMed ID: 6139893
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical inquiry: what is the best beta-blocker for systolic heart failure?
    Hulkower S; Aiken BA; Stigleman S
    J Fam Pract; 2015 Feb; 64(2):122-3. PubMed ID: 25671531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.
    Manz M; Reuter M; Lauck G; Omran H; Jung W
    Cardiology; 2003; 100(3):149-55. PubMed ID: 14631136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lessons from the BEAUTIfUL trial.
    Cardiovasc J Afr; 2009; 20(4):261-2. PubMed ID: 19701541
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ivabradine and outcomes in chronic heart failure.
    Kang SM; Won H; Hong N; Oh J
    Lancet; 2010 Dec; 376(9758):2069; author reply 2069-70. PubMed ID: 21168043
    [No Abstract]   [Full Text] [Related]  

  • 49. [The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure].
    Tereshchenko SN; Kositsyna IV; Dzhaiani NA; Golubev AV; Kochetov AG
    Kardiologiia; 2005; 45(6):19-22. PubMed ID: 16007029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
    Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
    Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ivabradine: heart rate and left ventricular function.
    Ferrari R
    Cardiology; 2014; 128(2):226-30. PubMed ID: 24776521
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment order in managing systolic ventricular dysfunction.
    MacFadyen RJ; Davis R
    J Am Coll Cardiol; 2005 Jul; 46(1):182-3; author reply 183. PubMed ID: 15992660
    [No Abstract]   [Full Text] [Related]  

  • 53. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
    Becher PM; Lindner D; Miteva K; Savvatis K; Zietsch C; Schmack B; Van Linthout S; Westermann D; Schultheiss HP; Tschöpe C
    Hypertension; 2012 May; 59(5):949-57. PubMed ID: 22493071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
    Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
    Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individualising heart failure patients to beta-blocker therapy.
    Cardiovasc J S Afr; 2004; 15(2):88, 91. PubMed ID: 15148544
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of propafenon on sinus node function].
    Sant'Anna JR; Belardinelli L; Lucchese FA
    Arq Bras Cardiol; 1980 Jul; 35(1):15-8. PubMed ID: 7224885
    [No Abstract]   [Full Text] [Related]  

  • 58. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
    Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of calcium ions on the rhythmic and contractile activities of the heart].
    Abinder AA; Khitrov NK; Aslaniants ZhE; Svistukhin AI
    Fiziol Zh SSSR Im I M Sechenova; 1975 Jan; 61(1):117-23. PubMed ID: 234088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.